Neoplasms by Site Clinical Trial
Official title:
A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Verified date | June 2024 |
Source | Bristol-Myers Squibb |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. The following tumor types are included in this study: Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that have NOT previously been treated with immunotherapy. NSCLC and melanoma that HAVE previously been treated with immunotherapy.
Status | Active, not recruiting |
Enrollment | 1499 |
Est. completion date | January 31, 2025 |
Est. primary completion date | October 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: - For Dose escalation: subjects with cervical, ovarian, bladder and colorectal cancer (CRC), head and neck, gastric and hepatocellular cancer naive to immuno-oncology agents; 1st line melanoma and 1st line/2nd line NSCLC; Renal Cell Carcinoma naive to IO; NSCLC progressing while on or after therapy with anti-PD1/anti-PDL-1 and melanoma subjects progressed while-on or after treatment with anti-PD1 or anti-PDL1 with or without anti-CTLA-4. - For Dose Expansion: all of the above in escalation except for cervical, ovarian, and CRC - Progressed, or been intolerant to, at least one standard treatment regimen, except for participants in 1st line cohorts. - ECOG performance status between 0 and 2 - At least 1 lesion with measurable disease at baseline - Availability of an existing tumor biopsy sample (and consent to allow pre-treatment tumor biopsy) Exclusion Criteria: - Primary central nervous system (CNS) tumors or solid tumors with CNS metastases as the only site of active disease - Autoimmune disease - Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent - Uncontrolled CNS metastases Other protocol defined inclusion/exclusion criteria could apply |
Country | Name | City | State |
---|---|---|---|
Australia | Local Institution - 0031 | Brisbane | Queensland |
Australia | Local Institution - 0033 | Melbourne | Victoria |
Australia | Local Institution - 0032 | Nedlands | Western Australia |
Australia | Local Institution - 0029 | North Sydney | New South Wales |
Australia | Local Institution - 0039 | Southport | Queensland |
Austria | Local Institution - 0023 | Wien | |
Austria | Local Institution - 0024 | Wien | |
Canada | Local Institution - 0050 | Quebec City | Quebec |
Canada | Local Institution - 0049 | Toronto | Ontario |
Denmark | Local Institution - 0028 | Copenhagen | |
Denmark | Local Institution - 0020 | Herlev | |
Finland | Local Institution - 0021 | Helsinki | Uusimaa |
France | Local Institution - 0038 | Marseille Cedex 5 | |
France | Local Institution - 0037 | Nantes Cedex 01 | |
France | Local Institution - 0036 | Pierre Benite Cedex | |
France | Local Institution - 0026 | Toulouse Cedex 9 | |
France | Local Institution - 0018 | Villejuif | |
Germany | Local Institution - 0007 | Essen | |
Germany | Local Institution - 0040 | Heilbronn | |
Germany | Local Institution - 0041 | Wuerzburg | |
Italy | Local Institution - 0014 | Milano | |
Italy | Local Institution - 0013 | Napoli | |
Italy | Local Institution - 0035 | Padova | |
Japan | Local Institution - 0052 | Chuo-ku | Tokyo |
Japan | Local Institution - 0055 | Nagoya-shi | Aichi |
Japan | Local Institution - 0059 | Sapporo-shi | Hokkaido |
Japan | Local Institution - 0054 | Sunto-gun | Shizuoka |
Netherlands | Local Institution - 0025 | Amsterdam | |
Norway | Local Institution - 0019 | Oslo | |
Spain | Local Institution - 0015 | Barcelona | |
Spain | Local Institution - 0046 | Malaga | |
Spain | Local Institution - 0006 | Pamplona | |
Switzerland | Local Institution - 0017 | Lausanne | |
Switzerland | Local Institution - 0016 | Zuerich | |
United Kingdom | Local Institution - 0022 | London | Greater London |
United Kingdom | Local Institution - 0027 | London | Greater London |
United Kingdom | Local Institution - 0034 | Manchester | |
United States | Local Institution - 0047 | Allentown | Pennsylvania |
United States | Local Institution - 0053 | Aurora | Colorado |
United States | Local Institution - 0004 | Baltimore | Maryland |
United States | Local Institution - 0001 | Boston | Massachusetts |
United States | Local Institution - 0003 | Chicago | Illinois |
United States | Local Institution - 0057 | Dallas | Texas |
United States | Local Institution - 0011 | Detroit | Michigan |
United States | Local Institution - 0045 | Houston | Texas |
United States | Local Institution - 0043 | La Jolla | California |
United States | Local Institution - 0005 | New York | New York |
United States | Local Institution - 0048 | Niles | Illinois |
United States | Local Institution - 0010 | Pittsburgh | Pennsylvania |
United States | Local Institution - 0002 | Portland | Oregon |
United States | Local Institution - 0051 | Rochester | Minnesota |
United States | Local Institution - 0044 | Saint Louis | Missouri |
United States | Local Institution - 0008 | Seattle | Washington |
United States | Local Institution - 0058 | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb |
United States, Australia, Austria, Canada, Denmark, Finland, France, Germany, Italy, Japan, Netherlands, Norway, Spain, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of participants with Adverse Events (AEs) | Grade 3 or higher per CTCAE v4 (Common Terminology Criteria for Adverse Events) | Approximately Up to 3 years | |
Primary | Proportion of participants with Serious Adverse Events (SAEs) | Grade 3 or higher per CTCAE v4 ( Common Terminology Criteria for Adverse Events) | Approximately Up to 3 years | |
Primary | Proportion of Deaths | Approximately Up to 3 years | ||
Primary | Proportion of participants with laboratory abnormalities in blood | Approximately Up to 3 years | ||
Primary | Proportion of participants with laboratory abnormalities in blood serum | Approximately Up to 3 years | ||
Primary | Proportion of participants with laboratory abnormalities in urine | Approximately Up to 3 years | ||
Primary | Objective response rate (ORR) | Approximately 3 years | ||
Primary | Disease control rate (DCR) | Approximately 3 years | ||
Primary | Duration of response (DOR) | Approximately 3 years | ||
Primary | Number of AEs in the Broad Scope MedDRA Anaphylactic Reaction SMQ | Approximately 3 years | ||
Primary | Proportion of participants with AEs leading to discontinuation of treatment | Approximately up to 3 years | ||
Secondary | Maximum observed serum concentration (Cmax) of BMS-986016 administered both alone and in combination with nivolumab | Approximately 2.3 years | ||
Secondary | Time of maximum observed serum concentration (Tmax) of BMS-986016 administered both alone and in combination with nivolumab | Approximately 2.3 years | ||
Secondary | Trough observed serum concentration (Ctrough) of BMS-986016 administered both alone and in combination with nivolumab | Approximately 2.3 years | ||
Secondary | Concentration at the end of a dosing interval (Ctau) [Eg: concentration at 336 hours] of BMS-986016 administered both alone and in combination with nivolumab | Approximately 2.3 years | ||
Secondary | Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986016 administered both alone and in combination with nivolumab | Approximately 2.3 years | ||
Secondary | Total body clearance (CLT) of BMS-986016 administered both alone and in combination with nivolumab | Approximately 2.3 years | ||
Secondary | Volume of distribution at steady state (Vss) of BMS-986016 administered both alone and in combination with nivolumab | Approximately 2.3 years | ||
Secondary | Effective elimination half-life that explains the degree of area under the concentration-time curve (AUC) accumulation observed (T-HALFeff AUC) of BMS-986016 administered both alone and in combination with nivolumab | Approximately 2.3 years | ||
Secondary | Effective elimination half-life that explains the degree of Cmax accumulation observed (T-HALFeff Cmax) of BMS-986016 administered both alone and in combination with nivolumab | Approximately 2.3 years | ||
Secondary | Accumulation index; ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986016 administered both alone and in combination with nivolumab | Approximately 2.3 years | ||
Secondary | Cmax accumulation index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax) of BMS-986016 administered both alone and in combination with nivolumab | Approximately 2.3 years | ||
Secondary | Ctau accumulation index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau) of BMS-986016 administered both alone and in combination with nivolumab | Approximately 2.3 years | ||
Secondary | Degree of fluctuation (DF) or fluctuation index ([Cmax - Ctau]/Css,avg]) of BMS-986016 administered both alone and in combination with nivolumab | Approximately 2.3 years | ||
Secondary | Immunogenicity measured by anti-drug antibody (ADA) for BMS-986016 (all participants) and nivolumab | Approximately 2.3 years | ||
Secondary | QTc interval from centrally read electrocardiograms (ECGs) | Approximately 2.3 years | ||
Secondary | Best overall response (BOR) | Approximately 3 years | ||
Secondary | ORR | Approximately 3 years | ||
Secondary | DCR | Approximately 3 years | ||
Secondary | Duration of response (DOR) | Approximately 3 years | ||
Secondary | Progression-free survival (PFS) rates | Up to approximately 3 years | ||
Secondary | Overall survival (OS) | Approximately 2 years | ||
Secondary | Number of AEs in the Narrow Scope MedDRA Anaphylactic Reaction SMQ | Approximately 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Completed |
NCT00377520 -
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05602935 -
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
|
Phase 2 | |
Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03656718 -
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05322486 -
Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
|
||
Recruiting |
NCT04566952 -
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT05770102 -
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
|
Phase 2/Phase 3 | |
Recruiting |
NCT01917279 -
Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
|
Phase 3 | |
Recruiting |
NCT01427400 -
The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction
|
Phase 4 | |
Completed |
NCT01472146 -
ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
|
Phase 2 | |
Completed |
NCT00050414 -
A Study of Trabectedin in Patients With Advanced Ovarian Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01037049 -
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
|
Phase 2 | |
Recruiting |
NCT04556071 -
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT02960724 -
uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer
|
Phase 2 | |
Completed |
NCT00562224 -
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
|
Phase 1 | |
Completed |
NCT04679675 -
Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial
|
N/A | |
Completed |
NCT04080843 -
Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
|
Phase 2 | |
Terminated |
NCT04644315 -
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT01556815 -
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
|
Phase 2 |